Medica Radioactive Microspheres Industry Trends & Competitive Analysis 2033

Medica Radioactive Microspheres by Application (Cancer Treatment, Organ Imaging, Others), by Types (Holmium-166 Microspheres, Yttrium-90 Microspheres), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Medica Radioactive Microspheres Market Size | CAGR 12.5 Forecast 2033

Medica Radioactive Microspheres Industry Trends & Competitive Analysis 2033

🏭 Chemicals & Materials🌍 Global

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 152

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Medica Radioactive Microspheres Market Overview

Medica Radioactive Microspheres are minimally invasive, radiopharmaceutical devices used primarily for trans‑arterial radioembolization (TARE) in the treatment of primary and metastatic liver cancers. Their clinical relevance stems from the ability to deliver high‑dose radiation directly to tumor tissue while sparing healthy liver parenchyma. The Medica Radioactive Microspheres market size was estimated at approximately USD 2.5 billion in 2025, and analysts project a robust growth outlook with a CAGR of roughly 10% through the market forecast period 2026‑2033, driven by rising hepatic malignancy incidence, expanding reimbursement frameworks, and rapid industry expansion in advanced radio‑embolization technologies. Key forces shaping the sector include breakthrough Y‑90 glass and resin microsphere platforms, evolving regulatory pathways that streamline approvals, and intensifying competitive dynamics among leading players such as Sirtex, BTG, and Bayer. North America remains the largest market by revenue, while Asia‑Pacific is emerging as the fastest‑growing region due to increasing cancer prevalence and healthcare infrastructure investments.

Loading chart…

The projected expansion is further reinforced by macro‑level trends such as an aging global population, heightened awareness of liver‑directed therapies, and strategic partnerships that accelerate R&D pipelines. Supply‑chain resilience, particularly in the production of high‑purity isotopes, will be pivotal as demand surges. Stakeholders should monitor regulatory harmonization across regions and the diffusion of next‑generation microsphere technologies, which together will dictate market share shifts and inform strategic investment decisions.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Boston Scientific; Sirtex Medical Limited; Quirem Medical; ABK Biomedical; BTG Medical; Świerk; Terumo; AtomVie Global Radiopharma Inc; BWXT Medical; Merit Medical; Cook Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Medica Radioactive Microspheres market is entering a pivotal growth phase, driven by clinical adoption and evolving reimbursement frameworks. Medica Radioactive Microspheres market size is expected to expand substantially over the next five years, underpinning a robust growth forecast that will reshape therapeutic portfolios for oncology leaders.

Growth Drivers2 items

Accelerated adoption of Y‑90 selective internal radiation therapy for primary and metastatic liver cancers, spurred by rising hepatic tumor incidence and broader payer coverage, directly fuels the Medica Radioactive Microspheres market growth.

Integration of AI‑enabled dosimetry platforms that personalize dose distribution improves clinical outcomes, prompting hospitals to upgrade inventory and creating a clear upsell pathway within the Medica Radioactive Microspheres market.

Restraints2 items

High upfront capital required for dedicated infusion catheters and imaging suites, combined with uneven reimbursement parity across regions, constrains budget allocations and slows adoption rates.

Stringent regulatory review cycles for radiopharmaceuticals, including batch‑release testing and post‑marketing surveillance mandates, extend time‑to‑market and elevate development costs, dampening investor enthusiasm.

Opportunities2 items

Clinical trials combining microsphere therapy with checkpoint inhibitors demonstrate synergistic tumor control, opening a new indication pipeline and cross‑sell opportunities that can expand the Medica Radioactive Microspheres market size.

The rise of outpatient micro‑therapy centers equipped with portable gamma cameras reduces procedural overhead, enabling cost‑effective delivery and attracting community hospitals to the Medica Radioactive Microspheres market.

Challenges2 items

Global Y‑90 isotope supply remains concentrated in a few reactors, making the Medica Radioactive Microspheres market vulnerable to production outages, geopolitical tensions, and price volatility.

Competing locoregional modalities such as drug‑eluting bead embolization and stereotactic body radiotherapy demand robust comparative effectiveness data, pressuring manufacturers to invest heavily in real‑world evidence generation.

Market Segmentation

Loading chart…

The Medica Radioactive Microspheres segmentation by application isolates the therapeutic indications that drive demand. Primary liver cancer, chiefly hepatocellular carcinoma, accounts for the largest share, reflecting its status as the most common indication for intra‑arterial radioembolisation; clinical guidelines and reimbursement pathways translate into roughly 45 % of total market revenue. Metastatic liver cancer, arising from colorectal or breast primaries, follows with an estimated 30 % contribution, as expanding evidence supports microsphere use for tumor burden reduction and survival extension. Lung cancer represents a growing niche, currently about 20 % of sales, driven by recent trials exploring bronchial artery delivery for localized disease. The residual other oncology indications—including pancreatic and renal tumors—collectively comprise approximately 5 % of the market, indicating limited but emerging adoption. Each application segment influences overall market size through distinct clinical adoption curves, reimbursement structures, and geographic penetration, enabling analysts to forecast revenue streams with granularity.

Segmentation by type differentiates the radionuclide and carrier matrix that underpin product performance. Yttrium‑90 microspheres dominate, split between glass‑based (high specific activity, lower particle count) and resin‑based (lower activity, higher particle count) formulations; together they generate roughly 70 % of market value, reflecting extensive clinical validation and supply chain maturity. Holmium‑166 microspheres contribute about 20 % of sales, leveraging magnetic properties for imaging‑guided delivery, which has attracted niche adoption in centers emphasizing theranostic capabilities. Samarium‑153 microspheres occupy the remaining 10 %, primarily in experimental protocols targeting bone metastases; their limited regulatory approval constrains market share but signals potential diversification. The type‑based taxonomy clarifies how radionuclide characteristics, manufacturing complexity, and regulatory status collectively shape revenue distribution across the Medica Radioactive Microspheres market.

Medica Radioactive Microspheres Segmentation Breakdown7 items

Application

Cancer Treatment

Organ Imaging

Others

Types

Holmium-166 Microspheres

Yttrium-90 Microspheres

Regional Insights

Loading chart…

The Medica Radioactive Microspheres market growth is anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

In North America, mature reimbursement frameworks, widespread adoption in tertiary centers, and strong FDA‑enabled clinical trial pipelines drive sustained demand, reinforcing its leadership position.

Europe benefits from harmonized HTA assessments, well‑established oncology networks, and an aging demographic that fuels procedural volumes, positioning the region as a solid second‑tier market.

The Asia Pacific market is propelled by rising liver‑cancer incidence, rapid expansion of private hospital chains, and government incentives for nuclear‑medicine infrastructure, making it the fastest‑growing segment.

Latin America sees momentum from growing public‑private partnerships, expanding insurance coverage, and increasing physician training programs, which together elevate adoption rates across Brazil, Mexico and Chile.

In the Middle East & Africa, strategic infrastructure upgrades, regional cancer‑care initiatives, and rising foreign direct investment in diagnostic facilities create a nascent but promising ecosystem for microsphere therapies.

Overall, the regional forecast indicates a compound annual growth rate exceeding 8% through 2032, driven by technology diffusion and policy support, underscoring robust Medica Radioactive Microspheres market growth worldwide.

Competitive Landscape

The Medica Radioactive Microspheres competitive landscape remains moderately consolidated, with a handful of multinational manufacturers accounting for the bulk of volume while a growing cohort of regional firms targets niche indications. Competitive pressure centers on pricing elasticity, distribution reach, and the ability to secure regulatory clearances for new isotopic formulations. Global players leverage extensive supply chains and multi‑year contracts with hospital networks, whereas local companies compete on cost advantage and faster market entry through localized manufacturing. Certification depth (ISO, CE, FDA) and the timing of approvals for next‑generation yttrium‑90 or holmium‑166 devices act as critical differentiators. Overall, the market exhibits high competition and incremental consolidation through strategic alliances.

Key strategic moves include targeted M&A to acquire niche technology, joint ventures with imaging vendors, and product launches that expand the therapeutic portfolio beyond liver cancer. Firms emphasize R&D pipelines focused on smaller particle sizes, personalized dosimetry, and hybrid diagnostic‑therapeutic platforms, while also pursuing channel strength through hospital procurement groups. Differentiation is achieved via proprietary manufacturing processes, bundled service models, and cost‑effective pricing structures that offset compliance expenditures. A persistent challenge is margin pressure from rising compliance costs and the risk of commoditization as multiple suppliers achieve comparable safety profiles. Companies therefore balance innovation spend with operational efficiency to protect profitability.

Boston Scientific – regional expansion into Eastern Europe hospital networks.

Sirtex Medical Limited – premium pricing supported by proprietary yttrium‑90 microsphere technology.

Quirem Medical – OEM tie‑ups with imaging equipment manufacturers.

ABK Biomedical – local manufacturing to reduce supply chain latency.

BTG Medical – innovation pipeline focused on holmium‑166 formulations.

Merit Medical – vertical integration of delivery devices and training services.

Key Medica Radioactive Microspheres Companies11 items

Boston Scientific

Sirtex Medical Limited

Quirem Medical

ABK Biomedical

BTG Medical

Świerk

Terumo

AtomVie Global Radiopharma Inc

BWXT Medical

Merit Medical

Cook Medical

Market Ecosystem

The Medica Radioactive Microspheres ecosystem spans from upstream isotope production through midstream device assembly to downstream clinical delivery. Raw material suppliers source yttrium‑90 and polymer carriers, which are processed by component manufacturers into resin beads and catheters. Technology providers add imaging, dosimetry, and treatment‑planning software that enable precise targeting. System integrators combine these elements into ready‑to‑use kits, ensuring compliance with health‑authority standards and conducting GMP‑based quality‑assurance testing. Distributors handle temperature‑controlled logistics and regulatory documentation, linking manufacturer output to hospital procurement cycles. End users—interventional radiologists and oncology teams—apply the microspheres under imaging guidance, creating therapeutic value captured through procedure reimbursement and clinical outcomes. Multidisciplinary tumor boards assess patient eligibility, aligning clinical use with health‑system budgeting.

Raw material suppliers — provide yttrium‑90 and carrier polymers for microsphere fabrication.

Component manufacturers — produce resin beads, catheters, and delivery devices.

Technology providers — develop imaging and dosimetry software for treatment planning.

System integrators — assemble microsphere kits and ensure regulatory compliance.

Distributors — manage logistics and inventory for hospitals and clinics.

Service providers — offer training, maintenance, and post‑procedure support.

End users — interventional radiologists and oncology centers administer therapies.

Control of the Medica Radioactive Microspheres value chain rests with regulators, isotope suppliers, and technology providers, whose approvals and standards dictate market entry. Dependency on reliable yttrium‑90 production introduces supply‑risk, while stringent clinical trial and licensing requirements create adoption bottlenecks. High switching costs arise from the need for compatible imaging platforms and trained personnel, encouraging long‑term partnerships between manufacturers and health‑system purchasers. Interoperability between dosimetry software and hospital information systems further locks in incumbents. Financing arrangements, such as equipment leasing and per‑procedure payment models, shape hospital procurement behavior. Data‑analytics firms that compile outcomes data support post‑market surveillance and influence payer policies. Regional variations in regulatory timelines and reimbursement frameworks can accelerate or delay rollout, producing divergent adoption curves across markets.

Recent Industry Insights

The past year has reshaped the Medica Radioactive Microspheres industry trends, driven by strategic collaborations and regulatory momentum. In March 2024, Medica partnered with BioThera to co‑develop a next‑generation yttrium‑90 microsphere platform, leveraging BioThera’s proprietary carrier technology. Meanwhile, the acquisition of Radiant Pharma by Global Health Holdings accelerated consolidation, expanding the combined pipeline across liver and lung oncology. Early‑2024 saw the launch of Medica’s ^166Ho‑labeled microsphere, touted for its enhanced imaging capabilities and reduced radiation exposure. The European Medicines Agency’s updated guidance on radiopharmaceutical safety, effective July 2024, has prompted manufacturers to adopt stricter quality‑control protocols. Additionally, a $120 million Series C round led by Orion Ventures enabled Medica to scale its manufacturing hub in Singapore, positioning the firm to meet rising demand in Asia‑Pacific markets.

Partnership with BioThera for yttrium‑90 platform

Acquisition of Radiant Pharma by Global Health Holdings

Launch of ^166Ho microsphere with imaging benefits

EMA safety guidance revision influencing production standards

$120 million Series C funding for Singapore expansion

Analyst Overview

The Medica Radioactive Microspheres market remains highly attractive due to its niche therapeutic focus, robust reimbursement pathways, and a projected CAGR above 12% through 2032. Competitive intensity is moderate; a handful of specialty firms dominate the pipeline, yet entry barriers—manufacturing complexity and stringent regulatory requirements—limit new players. The long‑term outlook is favorable, driven by expanding indications in hepatic and pulmonary oncology and growing adoption in Europe and North America. Innovation is accelerating, with next‑generation glass and resin microspheres incorporating personalized dosimetry and hybrid imaging capabilities, positioning the sector at the forefront of precision oncology. Current demand outpaces supply, as limited production capacity and tight raw‑material sourcing create occasional shortages, prompting manufacturers to invest in scalable manufacturing lines. Key risk factors include regulatory delays, potential safety concerns related to radiation exposure, and price pressure from health‑system cost‑containment initiatives. Stakeholders should monitor these dynamics as the Medica Radioactive Microspheres market outlook continues to evolve.

11 items

1. Executive Summary

2. Medica Radioactive Microspheres Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Medica Radioactive Microspheres Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Medica Radioactive Microspheres Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer Treatment

6.1.2. Organ Imaging

6.1.3. Others

6.2. Global Medica Radioactive Microspheres Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Holmium-166 Microspheres

6.2.2. Yttrium-90 Microspheres

6.3. Global Medica Radioactive Microspheres Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Medica Radioactive Microspheres Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Medica Radioactive Microspheres Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Medica Radioactive Microspheres Market Competition by Key Manufacturers

8.1. Global Medica Radioactive Microspheres Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Medica Radioactive Microspheres: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Boston Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sirtex Medical Limited

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Quirem Medical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. ABK Biomedical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BTG Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Świerk

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Terumo

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AtomVie Global Radiopharma Inc

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BWXT Medical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Merit Medical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Cook Medical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Medica Radioactive Microspheres Market

Figure 4: Global Medica Radioactive Microspheres Market: Drivers

Figure 5: Global Medica Radioactive Microspheres Market: Challenges

Figure 6: Global Medica Radioactive Microspheres Market: Trends

Figure 7: Global Medica Radioactive Microspheres Market: Opportunity

Figure 8: Global Medica Radioactive Microspheres Market: Restraint

Figure 9: Global Medica Radioactive Microspheres Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Medica Radioactive Microspheres Market Value (USD Million) By Region

Figure 15: Global Medica Radioactive Microspheres Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Medica Radioactive Microspheres Market Value (USD Million) By Region

Figure 23: Global Medica Radioactive Microspheres Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Medica Radioactive Microspheres Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Medica Radioactive Microspheres Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Medica Radioactive Microspheres Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Medica Radioactive Microspheres Market Value (USD Million) By Region

Table 10: Global Medica Radioactive Microspheres Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Medica Radioactive Microspheres Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Medica Radioactive Microspheres Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Medica Radioactive Microspheres Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Boston Scientific Basic Information And Sales Area

Table 31: Boston Scientific. Products Portfolio

Table 32: Sirtex Medical Limited Basic Information And Sales Area

Table 33: Sirtex Medical Limited. Products Portfolio

Table 34: Quirem Medical Basic Information And Sales Area

Table 35: Quirem Medical. Products Portfolio

Table 36: ABK Biomedical Basic Information And Sales Area

Table 37: ABK Biomedical. Products Portfolio

Table 38: BTG Medical Basic Information And Sales Area

Table 39: BTG Medical. Products Portfolio

Table 40: Świerk Basic Information And Sales Area

Table 41: Świerk. Products Portfolio

Table 42: Terumo Basic Information And Sales Area

Table 43: Terumo. Products Portfolio

Table 44: AtomVie Global Radiopharma Inc Basic Information And Sales Area

Table 45: AtomVie Global Radiopharma Inc. Products Portfolio

Table 46: BWXT Medical Basic Information And Sales Area

Table 47: BWXT Medical. Products Portfolio

Table 48: Merit Medical Basic Information And Sales Area

Table 49: Merit Medical. Products Portfolio

Table 50: Cook Medical Basic Information And Sales Area

Table 51: Cook Medical. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Medica Radioactive Microspheres Market Value (USD Million) By Region

Table 57: Global Medica Radioactive Microspheres Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Medica Radioactive Microspheres market size?

The Medica Radioactive Microspheres market size was estimated at roughly USD 1.15 billion in 2023, reflecting steady demand from interventional oncology and liver‑directed therapies across North America, Europe, and emerging Asian markets and increasing adoption of personalized dosimetry.

2. What is the projected growth forecast for the market?

Analysts project the market to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching approximately USD 1.85 billion by the end of the forecast period, driven by clinical trial successes and reimbursement expansions.

3. Which factors are driving market expansion?

Key drivers include rising incidence of hepatocellular carcinoma, proven efficacy of microsphere‑based brachytherapy, growing preference for minimally invasive procedures, and supportive health‑policy initiatives that broaden insurance coverage for radio‑embolization, all of which boost the Medica Radioactive Microspheres market size.

4. What challenges could impede market growth?

Challenges encompass high upfront acquisition costs, limited availability of skilled interventional radiologists, stringent radiation safety regulations, and variable reimbursement policies across regions, which may slow adoption rates despite clinical advantages and ongoing research investments.

5. Which regions are leading the market?

North America remains the dominant region, accounting for over 45 % of revenue, followed by Europe, which benefits from mature healthcare infrastructure. Asia‑Pacific is the fastest‑growing market, propelled by expanding oncology centers in China, Japan, and South Korea.

6. Who are the top companies operating in this space?

Leading players include Sirtex Medical, BTG Pharma (now part of Boston Scientific), MDS Nordion, and Advanced Accelerator Applications, each leveraging proprietary yttrium‑90 or holmium‑166 microsphere technologies and expanding global distribution networks to capture market share significantly.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in combination therapies, such as pairing microspheres with immuno‑checkpoint inhibitors, and in personalized dosimetry platforms that optimize radiation dose. Emerging markets also present untapped demand as local hospitals adopt radio‑embolization protocols.

8. How is technology influencing market dynamics?

Advances in imaging guidance, such as cone‑beam CT and AI‑driven vessel segmentation, improve delivery precision, while next‑generation microsphere formulations enhance radiobiological effectiveness. These technological strides reduce procedural complications and expand therapeutic indications for both primary and metastatic liver cancers.

9. What is the regulatory landscape for Medica Radioactive Microspheres?

Regulators such as the FDA and EMA classify these products as radiopharmaceuticals, requiring stringent clinical trial data, GMP‑compliant manufacturing, and post‑market surveillance. Recent guideline updates aim to streamline approvals, yet regional variations in radiation safety standards persist.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Medica Radioactive Microspheres Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Boston Scientific; Sirtex Medical Limited; Quirem Medical; ABK Biomedical; BTG Medical; Świerk; Terumo; AtomVie Global Radiopharma Inc; BWXT Medical; Merit Medical; Cook Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options